Trials / Sponsors / Point Therapeutics
Point Therapeutics
Industry · 7 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Terminated | Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Fa Carcinoma, Non-Small-Cell Lung, Lung Cancer, Neoplasms, Lung | Phase 3 | 2006-02-01 |
| Terminated | Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Fai Carcinoma, Non-Small Cell Lung | Phase 3 | 2006-01-01 |
| Terminated | Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas Pancreatic Cancer, Neoplasm Metastasis, Adenocarcinoma | Phase 2 | — |
| Completed | Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer Lung Cancer | Phase 2 | — |
| Completed | Study of Talabostat in Advanced Melanoma Melanoma, Skin Cancer | Phase 2 | — |
| Completed | Study of Talabostat and Cisplatin in Advanced Melanoma Melanoma, Skin Cancer | Phase 2 | — |
| Completed | Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL) Chronic Lymphocytic Leukemia | Phase 2 | — |